Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia.
David C KlonoffJordan MesslerTimothy ValkRam JagannathanFrancisco J PasquelGuillermo E UmpierrezPublished in: Journal of diabetes science and technology (2021)
Complications of Coronavirus Disease 2019 (COVID-19) occur with increased frequency in people admitted to the hospital with diabetes or hyperglycemia. The increased risk for COVID-19 infections in the presence of these metabolic conditions is in part due to overlapping pathophysiologic features of COVID-19, diabetes, and glucose control. Various antiviral treatments are being tested in COVID-19 patients. We believe that in these trials, it will be useful to evaluate treatment effect differences in patients stratified according to whether they have diabetes or hyperglycemia. In this way, it will be possible to better facilitate development of antiviral treatments that are most specifically beneficial for the large subset of COVID-19 patients who have diabetes or hyperglycemia.
Keyphrases
- coronavirus disease
- sars cov
- type diabetes
- cardiovascular disease
- glycemic control
- respiratory syndrome coronavirus
- clinical trial
- end stage renal disease
- ejection fraction
- diabetic rats
- healthcare
- newly diagnosed
- blood glucose
- chronic kidney disease
- prognostic factors
- weight loss
- patient reported outcomes
- study protocol
- open label